Clinical development failure
Pipeline value depends on demonstrating safety and efficacy in human trials.
- Scope
- vopimetostat, TNG456, TNG260
- Materiality
- high
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a U.S.-based precision oncology company focused on discovering and developing targeted cancer therapies for genetically defined patient populations. Its pipeline centers on small-molecule drug candidates designed to selectively attack cancer cells with specific genetic alterations while sparing normal cells.
−174,7 %
−162,9 %
+48,3 %
16.32
16.32
| % | |
|---|---|
| Clinical-stage oncology programs | 80% Drug candidates in human clinical development for genetically defined cancers. |
| Collaboration revenue | 20% Revenue recognized from partnered research and licensing arrangements. |
| Target discovery platform | 0% Internal discovery capabilities used to identify disease-relevant oncology targets. |
Tango Therapeutics does not sell commercial products today; its economic counterparties are pharmaceutical...
- Pharmaceutical collaboration partnersprimary
Buy access to discovery, research, and licensing rights in oncology programs.
- Future oncology treatment providerssecondary
Hospitals, cancer centers, and oncologists that would use approved therapies.
- Payers and reimbursement decision-makerssecondary
Assess clinical value and coverage for any approved cancer medicines.
- Research and translational science partnersemerging
Support target validation, biomarker work, and early-stage development.
The company is headquartered in the United States and conducts its core research and development activities from...
- •Headquartered in the United States
- •Boston, Massachusetts is a key office and laboratory location
- •Clinical and regulatory activity is centered in the U.S. and other major markets
- •Third-party API and drug-product supply includes China exposure
- •Future commercialization would likely expand into U.S. and ex-U.S. markets
Tango Therapeutics is focused on advancing genetically targeted oncology programs through clinical proof-of-concept and...
01
Advance vopimetostat and TNG456 in clinical developmentshort-term
Clinical validation is the main path to value creation for a pre-commercial oncology company.
02
Differentiate through genetically defined patient selectionmedium-term
Targeting MTAP-deleted tumors can improve selectivity and clinical relevance.
03
Expand combination and CNS opportunitiesmedium-term
Combination regimens and brain-penetrant assets broaden the addressable oncology market.
04
Preserve access to external funding and partnershipsshort-term
The company depends on collaboration revenue and capital markets to finance development.
The company faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk,...
Manufacturing and supply concentration
API and drug product rely on a small number of third-party suppliers.
- Scope
- Clinical trial supply and future commercial supply
- Materiality
- high
Capital dependence
The company must fund long-duration R&D before product revenue exists.
- Scope
- Equity, debt, and collaboration financing
- Materiality
- high
China-related supply chain exposure
One CDMO is located in China, creating geopolitical and logistics risk.
- Scope
- API and drug product sourcing
- Materiality
- high
Competitive pressure in oncology
Other companies are developing PRMT5 and related precision oncology programs.
- Scope
- PRMT5 inhibitor market and broader oncology pipeline
- Materiality
- high
Pricing and reimbursement risk
Future approved therapies may face coverage limits and pricing pressure.
- Scope
- U.S. and ex-U.S. commercialization
- Materiality
- medium
Revenue recognition for collaborations
Affects timing and volatility of reported revenue
Deferred revenue
Can materially shift revenue between quarters and years
Contingent milestone and royalty obligations
Affects future expense recognition and cash outflows
Lease accounting
Affects balance sheet leverage and operating expense presentation
Clinical trial and manufacturing accruals
Can affect R&D expense timing and comparability
SANGAMO THERAPEUTICS, INC
SGMOQ · Biological Products, (No Diagnostic Substances)
Sangamo Therapeutics is a U.S.-based genomic medicine company focused on developing therapies and enabling technologies built around zinc finger biology,…
TG THERAPEUTICS, INC.
TGTX · Pharmaceutical Preparations
TG Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases and related immune-mediated disorders.
MANGOCEUTICALS, INC.
MGRX · Services-Misc Health & Allied Services, NEC
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
UNITED THERAPEUTICS Corp
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
TherapeuticsMD, Inc.
TXMD · Pharmaceutical Preparations
: 29.4.2026